Publications (10) FABIO ARIAS BORDAJANDI publications

filter_list

2026

  1. Metabolic Pathways Linking Atherosclerotic Cardiovascular Disease With Metabolic Dysfunction-Associated Steatotic Liver Disease

    Current Atherosclerosis Reports, Vol. 28, Núm. 1

  2. Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis

    JHEP Reports, Vol. 8, Núm. 3

  3. Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1

    Journal of Medicinal Chemistry, Vol. 69, Núm. 3, pp. 2258-2286

2025

  1. Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery after Subarachnoid Hemorrhage

    Arteriosclerosis, Thrombosis, and Vascular Biology

2024

  1. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis

    Nature Metabolism, Vol. 6, Núm. 10, pp. 1939-1962

2022

  1. Bioactive imidamide-based compounds targeted against nitric oxide synthase

    Bioorganic Chemistry, Vol. 120

  2. NMR spectroscopy study of new imidamide derivatives as nitric oxide synthase inhibitors

    Magnetic Resonance in Chemistry, Vol. 60, Núm. 9, pp. 915-923

2021

  1. Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors

    Bioorganic and Medicinal Chemistry, Vol. 44

2018

  1. Thiadiazoline- And pyrazoline-based carboxamides and carbothioamides: Synthesis and inhibition against nitric oxide synthase

    Journal of Chemistry, Vol. 2018

2016

  1. Quinazolinones, Quinazolinthiones, and Quinazolinimines as Nitric Oxide Synthase Inhibitors: Synthetic Study and Biological Evaluation

    Archiv der Pharmazie, pp. 638-650